Shire (SHPG) Price Target Raised to $200.00 at B. Riley

Shire (NASDAQ:SHPG) had its target price hoisted by B. Riley to $200.00 in a report issued on Thursday morning. B. Riley currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on SHPG. Cowen set a $225.00 price objective on shares of Shire and gave the stock a buy rating in a research report on Friday, January 5th. JPMorgan Chase downgraded shares of Shire from an overweight rating to a neutral rating and reduced their price objective for the stock from $200.00 to $150.00 in a research report on Monday, February 19th. Zacks Investment Research raised shares of Shire from a sell rating to a hold rating in a research report on Friday, March 23rd. Piper Jaffray reaffirmed a hold rating on shares of Shire in a research report on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a buy rating in a research report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $204.64.

How to Become a New Pot Stock Millionaire

Shire stock traded up $0.48 during mid-day trading on Thursday, hitting $161.22. 1,939,078 shares of the stock were exchanged, compared to its average volume of 1,455,241. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.55 and a current ratio of 0.97. Shire has a 12 month low of $123.73 and a 12 month high of $192.15. The firm has a market cap of $49,404.84, a price-to-earnings ratio of 10.79, a PEG ratio of 1.28 and a beta of 1.31.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.58 by ($0.21). Shire had a return on equity of 14.19% and a net margin of 28.17%. equities research analysts predict that Shire will post 15.22 EPS for the current fiscal year.

The firm also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a $0.8937 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. Shire’s dividend payout ratio (DPR) is presently 6.93%.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SeaCrest Wealth Management LLC acquired a new stake in Shire in the 4th quarter valued at $107,000. Amica Retiree Medical Trust acquired a new stake in Shire in the 4th quarter valued at $120,000. Avestar Capital LLC acquired a new stake in Shire in the 4th quarter valued at $116,000. Steward Partners Investment Advisory LLC acquired a new stake in Shire in the 3rd quarter valued at $159,000. Finally, Benjamin F. Edwards & Company Inc. grew its position in Shire by 277.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 921 shares during the period. 19.58% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://weekherald.com/2018/04/20/shire-shpg-price-target-raised-to-200-00-at-b-riley.html.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply